{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:33:35Z","timestamp":1776800015807,"version":"3.51.2"},"reference-count":85,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["Specialized Center of Research Award"],"award-info":[{"award-number":["Specialized Center of Research Award"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["ASH Scholar Award"],"award-info":[{"award-number":["ASH Scholar Award"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3P50CA126752"],"award-info":[{"award-number":["3P50CA126752"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012173","name":"American Society for Blood and Marrow Transplantation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Adv Cell Gene Ther"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1002\/acg2.54","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T17:00:00Z","timestamp":1553792400000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CAR\u2010T cell therapy for non\u2010Hodgkin lymphomas: A new treatment paradigm"],"prefix":"10.1155","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa","family":"Hill","sequence":"first","affiliation":[{"name":"The Center for Cell and Gene Therapy Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premal","family":"Lulla","sequence":"additional","affiliation":[{"name":"The Center for Cell and Gene Therapy Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen E","family":"Heslop","sequence":"additional","affiliation":[{"name":"The Center for Cell and Gene Therapy Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2467-z"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1254547"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23524"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453308X343527"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.643404"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128843"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024"},{"key":"e_1_2_13_22_1","unstructured":"Kymriah[package insert].East Hanover NJ:Novartis Pharmaceuticals;2018."},{"key":"e_1_2_13_23_1","unstructured":"Yescarta[package insert].Santa Monica CA:Kite Pharma;2017."},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"issue":"1","key":"e_1_2_13_27_1","first-page":"577","article-title":"Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B\u2010cell lymphoma","volume":"130","author":"Schuster SJ","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7505"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2018-99-113714","article-title":"CAR22\/19 cocktail therapy for patients with refractory\/relapsed B\u2010cell malignancies","volume":"132","author":"Huang L","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/blood-2018-99-114396","article-title":"Phase I\/\/II trial of multi\u2010target chimeric antigen receptor modified T cells (4SCAR2.0) against relapsed or refractory lymphomas","volume":"132","author":"Chang L","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1182\/blood-2018-99-114527","article-title":"CD19 CAR T cell product exhibits high remission rate in adult relapsed and\/or refractory B\u2010cell non\u2010Hodgkin lymphoma","volume":"132","author":"Ying Z","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-99-113163","article-title":"ET190L1\u2010Artemis T cell therapy results in durable disease remissions with no cytokine release syndrome or neurotoxicity in patients with relapsed and refractory B\u2010cell lymphoma","volume":"132","author":"Ying Z","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2018-99-116741","article-title":"Anti\u2010CD30 chimeric antigen receptor T cell therapy for CD30+ relapsed\/refractory Hodgkin lymphoma and anaplastic large cell lymphoma patients","volume":"132","author":"Wang D","year":"2018","journal-title":"Blood"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.3003"},{"key":"e_1_2_13_36_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.001"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0126"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2456"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94306"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"e_1_2_13_52_1","article-title":"ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","author":"Lee DW","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"issue":"1","key":"e_1_2_13_55_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19\u2010targeted chimeric antigen receptor\u2010modified T\u2010cell immunotherapy","volume":"131","author":"Hill JA","year":"2018","journal-title":"Blood"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"issue":"25","key":"e_1_2_13_58_1","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent\u2010to\u2010treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner RA","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183459"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.10.002"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.2"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3025"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738245"},{"issue":"1","key":"e_1_2_13_69_1","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from Zuma\u20106: axicabtagene ciloleucel (Axi\u2010Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson CA","year":"2018","journal-title":"Blood"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0867"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752121"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3321"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0655"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222190"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329508"},{"issue":"6","key":"e_1_2_13_81_1","first-page":"1083","article-title":"First\u2010in\u2010man clinical trial of CAR NK\u201092 cells: safety test of CD33\u2010CAR NK\u201092 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang X","year":"2018","journal-title":"Am J Cancer Res"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.06.017"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.10.009"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.07.008"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3712"},{"key":"e_1_2_13_86_1","doi-asserted-by":"crossref","unstructured":"AbramsonJS PalombaML GordanL et al.Durable CR rates in relapsed\/refractory (R\/R) aggressive B\u2010NHL treated with the CD19\u2010Directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose\u2010finding and definition of pivotal. Cohort. Abstract presented at Blood;2017.","DOI":"10.1002\/hon.2437_127"}],"container-title":["ADVANCES IN CELL AND GENE THERAPY"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facg2.54","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acg2.54","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acg2.54","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acg2.54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T05:54:48Z","timestamp":1643349288000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acg2.54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1002\/acg2.54"],"URL":"https:\/\/doi.org\/10.1002\/acg2.54","archive":["Portico"],"relation":{},"ISSN":["2573-8461","2573-8461"],"issn-type":[{"value":"2573-8461","type":"print"},{"value":"2573-8461","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"2018-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}